EichorEICHOR
Condition: Egfr Exon 19 Deletion Mutation Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Egfr Exon 19 Deletion Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
Phase N/A · 1 location(s) · Our Lady of the Lake Hospital · NCT06659458A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Phase 1/Phase 2 · 42 location(s) · BlossomHill Therapeutics · NCT06706076Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT06574347Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Canc
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07505173Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Ca
Phase N/A · 16 location(s) · GFPC Investigation · NCT07563205
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.